Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934920 | 1.00 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3HTR1ACYP2D6 | |
| SCHEMBL934190 | 1.00 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3HTR1ACYP2D6 | |
| SCHEMBL1060216 | 0.87 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL934805 | 0.87 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1054550 | 0.87 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1060219 | 0.87 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1054553 | 0.87 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1060491 | 0.87 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL934952 | 0.83 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1058351 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454234-B1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9227933-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150126577-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-05-07 | — | — | US | disclosed |
| EP-2454234-A2 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | Theravance, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110257243-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7994209-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| WO-2011008666-A2 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110009465-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126577-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | SLC6A2 3/4885SLC6A4 2/4885SLC6A3 6/4885 |
| US-20110009465-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | SLC6A2 3/4885SLC6A4 2/4885SLC6A3 6/4885 |
| US-20110257243-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | SLC6A2 3/4885SLC6A4 2/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.